Event JSON
{
"id": "bd78da83ea7580737b0ab8486af0cbaa405bec8e38df2f7641cc90dacf3e8737",
"pubkey": "af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"created_at": 1738156369,
"kind": 1,
"tags": [
[
"r",
"https://en.globes.co.il/en/article-teva-falls-sharply-on-disappointing-2025-guidance-1001500783"
],
[
"subject",
"Teva falls sharply on disappointing 2025 guidance"
],
[
"published_at",
"1738162904"
],
[
"image",
"https://res.cloudinary.com/globes/image/upload/t_800X392/v1683725056/direct/Richard_Francis_Teva_by_Elad_Malka-207278_Large_ivg4zc.jpg"
],
[
"p",
"af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://res.cloudinary.com/globes/image/upload/t_800X392/v1683725056/direct/Richard_Francis_Teva_by_Elad_Malka-207278_Large_ivg4zc.jpg"
],
[
"t",
"unkown:perspective"
],
[
"summary",
"Teva Pharmaceutical Industries Ltd. published its fourth quarter and full year 2024 financial results, reporting revenue of $4.2 billion and non-GAAP earnings per share of $0.71, above analysts' expectations. However, the company's 2025 outlook was disappointing, with revenue guidance below expectations. Teva CEO Richard Francis highlighted the company's successful 2024, driven by its generic products and key innovative products, and expressed excitement for further progress in 2025."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqg90j3ltrtp2jj5xkjxthk59zwtt3092n2jeeyezulpa4qnyur5c0qh5y6qj\nhttps://res.cloudinary.com/globes/image/upload/t_800X392/v1683725056/direct/Richard_Francis_Teva_by_Elad_Malka-207278_Large_ivg4zc.jpg\nThe Israeli pharmaceuticals company reported strong fourth quarter results but its 2025 outlook did not meet expectations.\nhttps://en.globes.co.il/en/article-teva-falls-sharply-on-disappointing-2025-guidance-1001500783",
"sig": "1709f1e8318c9c2bdfc910300ec958821e7cf25964163e5e1c5f2a97e3be942f770f28c2f5072930181b68ebabfaeee254b13ea97448158798ba6952ea9b31f1"
}
